Posted by Michael Wonder on 23 Nov 2015
European Commission grants marketing authorization for Gilead’s single tablet regimen Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) for the treatment of HIV-1 infection
23 November 2015 - Genvoya is the first TAF-based regimen to receive marketing authorization in the European Union.
